Expert Insights

Prof Nicolas Girard, MD, discusses primary results from the phase 3 PAPILLON study comparing amivantamab plus chemotherapy vs chemotherapy alone for the first-line treatment of patients with EGFR exon 20 insertion-mutated advanced NSCLC.

Tina Cascone, MD, PhD, discusses results from the phase 3 CheckMate 77T trial evaluating neoadjuvant nivolumab plus chemotherapy vs placebo plus chemotherapy followed by surgery and adjuvant nivolumab vs placebo for previously untreated,...

Prof James Catto, MBChB, PhD, FRCS, discusses the first randomized data from Cohort 1 of the THOR-2 trial investigating erdafitinib vs intravesical chemotherapy in high-risk FGFR-altered non–muscle-invasive bladder cancer whose disease...

At the 2023 ESMO Annual Congress, Sherene Loi shares results from the CheckMate 7FL trial evaluating nivolumab vs placebo plus neoadjuvant chemotherapy among patients with high-risk, ER-positive/HER2-negative breast cancer.

Anthony Hunter, MD, discusses the role of interferon regimens for patients with myeloproliferative neoplasms, including polycythemia vera and essential thrombocythemia.

At the 2023 EANM meeting, Oliver Sartor, MD, discussed identifying biomarkers to predict resistance to Lutetium-177–PSMA-617 using circulating tumor DNA among patients with metastatic castration-resistant prostate cancer.

More patients achieved transfusion-independence and an increase in hemoglobin levels with luspatercept versus epoetin alfa, according to data presented at the SOHO 2023 annual meeting by Guillermo Garcia-Manero, MD.

At the Great Debates & Updates in Lung Cancer meeting, Chrisitian Rolfo, MD, PhD, discussed the use of ctDNA to monitor patients with lung cancers.

At the Great Debates & Updates in Lung Cancer meeting in New York, New York, Karen Reckamp, MD, debated in favor of using chemotherapy plus immunotherapy for patients with NSCLC and PD-L1 expressions of